Related Experiment Videos

Multiple low-dose streptozocin-induced diabetes in NOD-scid/scid mice in the absence of functional lymphocytes

I C Gerling1, H Friedman, D L Greiner

  • 1Jackson Laboratory, Bar Harbor, ME 04609.

Diabetes
|March 1, 1994
PubMed

Insights

Multiple low-dose streptozocin (MD-STZ) induces hyperglycemia in mice independently of T-cells and B-cells. This contrasts with spontaneous diabetes, suggesting different pathogenic mechanisms for MD-STZ-induced hyperglycemia versus autoimmune diabetes.

Area of Science:

  • Immunology
  • Endocrinology
  • Diabetes Research

Background:

  • The role of T-cells in streptozocin-induced diabetes is debated.
  • Murine models are crucial for understanding diabetes pathogenesis.

Purpose of the Study:

  • To investigate if T-cells are required for multiple low-dose streptozocin (MD-STZ)-induced hyperglycemia.
  • To compare the pathogenesis of MD-STZ-induced hyperglycemia with spontaneous diabetes.

Main Methods:

  • Utilized severe combined immunodeficiency (scid) mice (NOD-scid/scid and C.B.-17-scid/scid) lacking functional T-cells and B-cells.
  • Administered MD-STZ to scid and non-scid mice.
  • Performed adoptive transfer of splenocytes from diabetic and MD-STZ-treated donors.

Main Results:

  • MD-STZ induced hyperglycemia in scid mice, even at higher levels than in non-scid controls.
  • Splenocytes from spontaneously diabetic NOD mice transferred diabetes, but not those from MD-STZ-treated mice.
  • MD-STZ-induced hyperglycemia was observed in the absence of autoimmune markers like insulitis.

Conclusions:

  • MD-STZ-induced hyperglycemia is not mediated by T-cell or B-cell-dependent autoimmune mechanisms.
  • The pathogenesis of MD-STZ-induced hyperglycemia differs significantly from spontaneous autoimmune diabetes in NOD mice.

Related Concept Videos